Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Biond Biologics.

    Client Virtual Booth

    BIOND BIOLOGICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Biond Biologics
    Israel Flag
    Country
    Country
    Israel
    Address
    Address
    Misgav Industrial Park
    Telephone
    Telephone
    +972-4-8844337
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.biondbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biond-biologics-ltd
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial

    Details:

    BND-22 (SAR444881), is a humanized IgG4, antagonist antibody targeting the ILT2 receptor in development for the treatment of solid tumors, is an inhibitory receptor expressed on both innate and adaptive immune cells that binds MHC class I molecules.


    Lead Product(s): BND-22,Pembrolizumab

    Therapeutic Area: Oncology Product Name: SAR444881

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 23, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Biond Biologics to Present at the Raymond James LILRB/ILT Symposium

    Details:

    BND-22 (SAR444881), a novel immune checkpoint inhibitor targeting the Immunoglobulin-like transcript receptor 2 or ILT2, enhances anti-tumor activity of T cells and NK cells.


    Lead Product(s): BND-22,Pembrolizumab,Cetuximab

    Therapeutic Area: Oncology Product Name: BND-22

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Sanofi

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 20, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Biond Biologics Announces Closing of $15 Million Series C Financing

    Details:

    The financing has sopported the development of BND-22 (SAR444881), the company’s Ig-Like Transcript 2 (ILT2) receptor-blocking antibody, and the first patient has been dosed in the first-in-human, phase 1 clinical trial of BND22.


    Lead Product(s): BND-22,Pembrolizumab

    Therapeutic Area: Oncology Product Name: SAR444881

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Deep Insight

    Deal Size: $15.0 million Upfront Cash: Undisclosed

    Deal Type: Series C Financing November 03, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor

    Details:

    BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors.


    Lead Product(s): BND-22

    Therapeutic Area: Oncology Product Name: BND-22

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Sanofi

    Deal Size: $1,125.0 million Upfront Cash: $125.0 million

    Deal Type: Licensing Agreement January 12, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search